Gara Jalqabaatti › Burkitt Lymphoma › Oklahoma › Oklahoma City
Qorannoo klinikaalii Burkitt Lymphoma Oklahoma City, OK keessatti
Qorannoo 7 Burkitt Lymphoma f Oklahoma City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Namoota walitti qabaa jiraSadarkaa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Namoota walitti qabaa jiraSadarkaa 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Namoota walitti qabaa jiraSadarkaa 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Qorannoo Burkitt Lymphoma magaalota biroo keessatti
- Houston, TXQorannoo 21
- Philadelphia, PAQorannoo 16
- Milwaukee, WIQorannoo 16
- Chicago, ILQorannoo 15
- Cincinnati, OHQorannoo 13
- New York City, NYQorannoo 13
- Atlanta, GAQorannoo 12
- Aurora, COQorannoo 11
- Seattle, WAQorannoo 11
- Durham, NCQorannoo 10
- Boston, MAQorannoo 10
- Kansas City, MOQorannoo 10
Qorannoo biroo Oklahoma City keessatti
- Kansara Qara'a Non-Small CellQorannoo 28
- Kansarii OvariiQorannoo 28
- Kansa EndometiriyaaliiQorannoo 25
- Kansarii ColorectalQorannoo 22
- Kansarii ProstateQorannoo 21
- Dhibee QaraQorannoo 19
- Saree OljooQorannoo 17
- Kansara MetastatikiiQorannoo 16
- Saree (Gosoota Hunda)Qorannoo 14
- Leukemia Myeloidii HamaaQorannoo 14
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 13
- Dukkana BladderQorannoo 11
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.